Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care
VAUGHAN, Ontario / Jun 17, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22.
Data presentations highlight the results of several studies evaluating consumer, pharmaceutical and vision care products from the company’s broad eye care portfolio, in addition to evaluations of the dry eye treatment landscape and overall disease burden.
Educational sessions will feature innovations in clinical diagnosis and treatment of dry eye, including technological advancements.
The complete list of Bausch + Lomb scientific presentations as well as details for the featured education events is as follows:
Poster Presentations
Oral Presentation
Saturday, June 22
Featured Education Events
Saturday, June 22
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
© 2024 Bausch + Lomb.
MTB.0240.USA.24
Last Trade: | US$14.52 |
Daily Change: | -0.25 -1.69 |
Daily Volume: | 669,512 |
Market Cap: | US$5.100B |
June 10, 2024 June 03, 2024 May 28, 2024 May 01, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB